HUTCHMED (China) Limited (previously Chi-Med) is set to lead Chinese biotechs' latest fundraising rounds in June.
HutchMed announced on 18 June that it is looking to raise up to HKD4.7bn ($602.8m) in an initial public offering on the Hong Kong Stock Exchange (HKEX)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?